The Enterprise Value as of November 2024 (TTM) for ALX Oncology Holdings Inc. (ALXO) is 68.10M

According to ALX Oncology Holdings Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 68.10M. This represents a change of -83.80% compared to the average of 420.38M of the last 4 quarters.

ALX Oncology Holdings Inc. (ALXO) Historical Enterprise Value (quarterly & annually)

How has ALXO Enterprise Value performed in the past?

The mean historical Enterprise Value of ALX Oncology Holdings Inc. over the last ten years is 1.01B. The current 68.10M Enterprise Value has changed 573.59% with respect to the historical average. Over the past ten years (40 quarters), ALXO's Enterprise Value was at its highest in in the December 2020 quarter at 2.81B. The Enterprise Value was at its lowest in in the June 2019 quarter at 0.

ALX Oncology Holdings Inc. (ALXO) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of ALX Oncology Holdings Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

ALX Oncology Holdings Inc. (ALXO) Average Enterprise Value

How has ALXO Enterprise Value performed in the past?

The current Enterprise Value of ALX Oncology Holdings Inc. (ALXO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

ALX Oncology Holdings Inc. (ALXO) Enterprise Value vs. Peers

How is ALXO’s Enterprise Value compared to its peers?

ALX Oncology Holdings Inc.’s Enterprise Value is greater than Cabaletta Bio, Inc. (-63983636.00), greater than Viracta Therapeutics, Inc. (10.17M), less than EyePoint Pharmaceuticals, Inc. (552.94M), less than Biomea Fusion, Inc. (154.99M), less than Crinetics Pharmaceuticals, Inc. (4.93B), less than Immatics N.V. (696.05M), greater than BioAtla, Inc. (20.64M), greater than Aerovate Therapeutics, Inc. (46.23M), less than Dyne Therapeutics, Inc. (2.51B), less than Edgewise Therapeutics, Inc. (3.01B), less than Cullinan Oncology, Inc. (630.54M), less than Stoke Therapeutics, Inc. (457.69M), less than Mineralys Therapeutics, Inc. (523.81M), less than Century Therapeutics, Inc. (104.89M), less than C4 Therapeutics, Inc. (307.45M), less than TCR2 Therapeutics Inc. (79.12M), less than Revolution Medicines, Inc. (9.43B), less than Black Diamond Therapeutics, Inc. (139.97M), greater than Atreca, Inc. (-8620212.00), greater than Passage Bio, Inc. (24.72M),

Build a custom stock screener for ALX Oncology Holdings Inc. (ALXO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ALX Oncology Holdings Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

ALX Oncology Holdings Inc. (ALXO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like ALX Oncology Holdings Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.